BI gets nod from NICE for VTE after surgery
German drug major Boehringer Ingelheim has received a UK National Institute for Health and Clinical Excellence (NICE) recommendation for Pradaxa (dabigatran etexilate), to receive an additional indication as an option for the primary prevention of venous thromboembolic events in adults who have undergone elective total hip or knee replacement surgery.
Final NICE guidance for National Health Service clinical practise is expected to be issued shortly, says the firm. Pradaxa was approved for marketing in all EU member countries by the European Medications Agency (EMEA) in March 2008, and has already received positive recommendations from local Health Technology bodies in Scotland (Scottish Medicines Consortium) and Denmark (IRF). The drug has been available in Germany and the UK since April, and has marketing approval in Canada.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze